


Cell and gene therapy logistics

Cell and gene therapies (CGTs) represent the leading edge of biomedical research. Autologous and allogeneic cell, gene, and tissue therapies are transforming healthcare and are demonstrating dramatic results. CGTs come with unique logistic requirements that add complexity and risk to supply chains.

Access to advanced therapeutic medicinal products depends on product stability and a highly controlled supply chain to reach patients safely.

Explore our infographic below to learn more.



Did you know?

Cryogenic preservation's role in CGT logistics is essential

59%¹

of sponsors with CGTs in clinical trials indicated their need for third-party logistics partners with global cryogenic capabilities will grow significantly.

[Learn more](#)

Learn more in our white paper: [Cold hard facts about cryogenic cell and gene therapy logistics](#)

Industry agrees: Spending on cryogenic logistics to accelerate

100%¹

of CGT developers said they plan to accelerate spending in the next 12 months with third-party logistics partners with comprehensive global cryogenic capabilities.

Cell and gene therapy cryogenic logistics needs set to grow at an increasing pace

3,649

Cell and gene therapies (including genetically modified cell therapies, such as CAR-T cell therapies) were in development from preclinical through pre-registration at the end of 2022.² According to CGT companies, trials and therapies won't advance without third-party logistics partners providing a global network of cryogenic capabilities.

⁽¹⁾ Data derived from the World Courier survey 2021

⁽²⁾ <https://asgct.org/global/documents/asgct-citeline-q3-2022-report.aspx>

World Courier designs tailored logistics solutions to fit your CGT logistics requirements.

[Find out how we manage the complex with care](#)